Discontinued — last reported Q4 '25
Supplemental
New Operating Lease ROU
Neurocrine Biosciences New Operating Lease ROU increased by 100.0% to $0 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $262.6M to $0.
Analysis
StatementCash Flow Statement
SectionSupplemental
CategoryLeverage
SignalContext dependent
VolatilityModerate
First reportedQ1 2018
Last reportedQ4 2025Feb 11, 2026
How to read this metric
Higher values indicate an expansion of the company's physical footprint or equipment base through leasing arrangements.
Detailed definition
This represents the non-cash value of right-of-use assets recognized on the balance sheet in exchange for new operating...
Peer comparison
Commonly reported under ASC 842 lease accounting standards; comparable across companies with significant real estate or equipment leases.
Metric ID:
amzn_rou_asset_operating_lease_noncashHistorical Data
11 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.6M | $0 | $1.8M | $0 | $0 | $0 | $0 | $199M | $262.6M | -$3.4M | $0 |
| QoQ Change | — | -100.0% | — | -100.0% | — | — | — | — | +32.0% | -101.3% | +100.0% |
| YoY Change | — | — | — | — | -100.0% | — | -100.0% | — | +32.0% | — | -100.0% |
Range-$3.4M – $262.6M
CAGR-100.0%
Avg YoY Growth-67.0%
Median YoY Growth-100.0%
New Operating Lease ROU at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's new operating lease rou?
- Neurocrine Biosciences (NBIX) reported new operating lease rou of $0 in Q4 2025.
- How has Neurocrine Biosciences's new operating lease rou changed year-over-year?
- Neurocrine Biosciences's new operating lease rou decreased by 100.0% year-over-year, from $262.6M to $0.
- What does new operating lease rou mean?
- The value of new leased assets recognized without an immediate cash payment.